[
  {
    "question": "Type2 CMT patient what is the typical feature:",
    "option_a": "SNAP drop",
    "option_b": "Affect UL more than LL",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Charcot\u2010Marie\u2010Tooth (CMT) disease is an inherited peripheral neuropathy. Type 2 (CMT2) is the axonal variant as opposed to the demyelinating type (CMT1). The core concept in CMT2 is that the primary pathology is axonal degeneration, not myelination defects. In CMT2, mutations in various genes lead to progressive axonal loss. Because the myelin sheath remains essentially intact, conduction velocities on nerve conduction studies are nearly normal; however, the amplitudes (both compound muscle action potentials and sensory nerve action potentials or SNAPs) are reduced\u2014a phenomenon sometimes described as a 'SNAP drop'. This contrasts with CMT1 where demyelination causes uniformly slowed conduction velocities. Patients typically present with slowly progressive, symmetric distal weakness and atrophy (often with foot drop and high arches) predominantly in the lower extremities. Sensory deficits in a glove-and-stocking distribution are common. The fact that SNAP amplitudes decrease in CMT2 supports this answer. Diagnosis relies on clinical findings, family history, genetic testing, and nerve conduction studies. Key differentials include CMT1 (which shows markedly slowed conduction velocities) and acquired peripheral neuropathies. Electrodiagnostic studies are essential to differentiate axonal versus demyelinating processes. There is no curative treatment for CMT2; management is supportive. First-line management involves physical therapy, occupational therapy, and orthotic support (e.g., ankle\u2013foot orthoses). Pain management, bracing, and surgical interventions (such as tendon transfers) may be considered in select cases. In pregnancy and lactation, conservative management remains the same with a focus on maintaining mobility, and any pharmacological interventions must consider fetal and neonatal safety. Option A (SNAP drop) is correct because the electrophysiological hallmark of CMT2 is a reduction in SNAP amplitudes while conduction velocities remain near normal. Option B (Affect UL more than LL) is incorrect since typically the lower extremities are predominantly involved. 1. CMT2 is an axonal neuropathy with normal conduction velocities and reduced SNAP amplitudes. 2. Lower limb involvement is generally more pronounced than upper limb involvement. 3. Genetic testing is increasingly used to specify the subtype of CMT. Recent research confirms that CMT2 primarily involves axonal degeneration and supports the use of advanced genetic panels for diagnosis. Current guidelines emphasize multidisciplinary supportive care, and new studies continue to explore targeted molecular therapies.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Most common presentation of post polio syndrome:",
    "option_a": "Asymptomatic",
    "option_b": "Aseptic meningitis",
    "option_c": "Flu like symptoms",
    "option_d": "",
    "option_e": "",
    "correct_answer": "D (which should represent new-onset muscle weakness and fatigue)",
    "subspecialty": "Neuromuscular",
    "explanation": "Post-polio syndrome (PPS) is a condition affecting polio survivors, typically emerging decades after the initial illness. Its core concept involves the gradual deterioration of motor neurons that had previously reinnervated muscles after the original insult. The leading hypothesis for PPS is that after the initial polio infection, surviving motor neurons branch out to reinnervate muscle fibers. Over decades, these enlarged motor units become overtaxed, leading to gradual axonal degeneration and resultant muscle weakness, fatigue, and pain. This process is not mediated by an active poliovirus infection but by the 'aging' of these compensatory motor units. Clinically, PPS often presents with gradual new muscle weakness, fatigue, and muscle and joint pain. It typically affects muscles that were previously weakened during the acute poliomyelitis episode. The most common and concerning symptom is new-onset muscle weakness, which distinguishes it from asymptomatic states or transient flu-like presentations. Diagnosis is primarily clinical, based on a documented history of poliomyelitis and a latent interval of stable function followed by new weakness. Differential diagnoses include cervical spondylosis, amyotrophic lateral sclerosis (ALS), and other neuromuscular disorders. Electromyography (EMG) and muscle strength testing help to confirm the diagnosis while ruling out other conditions. Management is supportive. First-line strategies include tailored exercise programs, energy conservation techniques, and physical therapy to improve endurance while avoiding overuse. Analgesics may be used for pain control. In pregnancy and lactation, nonpharmacological interventions are preferred; any medication should be chosen carefully with regard to fetal safety, and physiotherapy remains the mainstay. Option A (\u2018Asymptomatic\u2019) is incorrect because PPS is characterized by the appearance of new symptoms. Option B (\u2018Aseptic meningitis\u2019) does not characterize PPS and is instead seen in different viral or inflammatory conditions. Option C (\u2018Flu like symptoms\u2019) is not a typical presentation of PPS. The intended Option D\u2014though missing from the listing\u2014should indicate the most common symptoms of PPS: new-onset muscle weakness and fatigue. 1. PPS typically develops 15-40 years after the initial polio infection. 2. The hallmark of PPS is new muscle weakness in previously affected muscles. 3. A thorough history of past poliomyelitis is critical for diagnosis. Recent consensus guidelines emphasize the role of individualized exercise programs and energy management in PPS. Ongoing research is exploring potential biomarkers for early diagnosis and interventions to slow the progression of motor unit degeneration.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "pt with C5-C6 radiculopathy what muscle involved:",
    "option_a": "infraspinatus",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Radiculopathy at the C5-C6 level involves compression or irritation of the nerve roots corresponding to these segments. Muscles innervated by these roots, including components of the shoulder girdle and upper arm, are impacted. Compression, herniated discs, or foraminal stenosis affecting the C5 and C6 nerve roots can lead to deficits in the distribution of these nerves. The infraspinatus muscle, innervated by the suprascapular nerve (which arises predominantly from C5 and C6), is commonly affected because of its reliance on these nerve roots for proper function. Patients with C5-C6 radiculopathy often present with shoulder pain, weakness in shoulder abduction and external rotation, and sometimes sensory changes. Weakness in the infraspinatus can manifest as difficulty with external rotation of the arm. Diagnosis relies on a combination of clinical examination (testing for weakness in muscles such as the deltoid and infraspinatus), imaging studies (MRI for disc herniation or foraminal narrowing), and electrodiagnostic studies (EMG to confirm radicular involvement). Differential diagnoses include rotator cuff tears and shoulder impingement syndromes, which can be differentiated based on imaging and specific physical exam maneuvers. First-line treatment is conservative and includes physical therapy, nonsteroidal anti-inflammatory drugs (NSAIDs), and activity modification. Epidural steroid injections may be used if initial measures fail. Surgical options are reserved for refractory cases or when neurological deficits worsen. In pregnancy and lactation, conservative management is preferred and NSAIDs (with appropriate gestational restrictions) and physical therapy are the mainstays. Option A (infraspinatus) is correct given that the muscle is innervated by the suprascapular nerve derived from C5 and C6. The other options are not provided, but among typical choices, the infraspinatus is a representative muscle of this radicular level involvement. 1. C5-C6 radiculopathy often impacts muscles of the shoulder girdle including the deltoid and infraspinatus. 2. Infraspinatus weakness leads to impaired external rotation of the arm. 3. Electrophysiological studies help differentiate radiculopathy from other shoulder pathologies. Both conservative and interventional treatments are supported by current guidelines, with a trend toward early physical therapy to improve outcomes. Updated research continues to refine the indications for injections and surgical intervention in cervical radiculopathy.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "pt with shoulder pain, had weakness in forearm and arm, what most common involved:",
    "option_a": "Upper trunk",
    "option_b": "Lower trunk",
    "option_c": "Upper and lower trunk",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "This question addresses brachial plexus involvement, specifically identifying which portion of the plexus is most commonly affected in patients presenting with shoulder pain and weakness of the arm. The brachial plexus is divided into roots, trunks, divisions, cords, and branches, with the upper trunk (formed by C5 and C6 nerve roots) being particularly vulnerable. Injury or pathology of the upper trunk (often seen in traction injuries or inflammatory conditions such as neuralgic amyotrophy) affects the muscles innervated by the C5-C6 distribution. This results in pain and weakness primarily in the shoulder and proximal arm. Although the forearm may be affected indirectly (e.g., weakness in muscles like the biceps that contribute to forearm function), the primary issue is with the upper trunk distribution. Patients with upper trunk lesions typically present with shoulder pain and weakness in the muscles responsible for shoulder abduction, external rotation, and elbow flexion. This presentation is classically seen in Erb-Duchenne palsy. The involvement of the forearm muscles (such as those engaged during elbow flexion) further supports upper trunk distribution involvement. Diagnosis is made clinically through history and physical examination. Neurological evaluation including muscle strength testing, reflexes, and nerve conduction studies can help localize the lesion. Differential diagnoses include lower trunk lesions (which predominantly affect hand and intrinsic muscles), complete brachial plexus injuries, and rotator cuff pathologies. Imaging (e.g., MRI or CT myelogram) may be indicated to evaluate for structural causes. The first-line management of upper trunk brachial plexopathy is conservative, including rest, physical therapy, and NSAIDs for pain relief. If symptoms persist, options include corticosteroid therapy or nerve blocks. Surgical intervention is reserved for cases with severe or progressive neurological deficits. In the context of pregnancy and lactation, conservative measures (physical therapy and safe analgesics) are preferred, with caution toward the use of systemic steroids or other medications unless absolutely necessary. Option A (Upper trunk) is correct because it is the most commonly involved portion in cases of shoulder pain with corresponding arm weakness. Option B (Lower trunk) would typically present with deficits in the hand (Klumpke paralysis). Option C (Upper and lower trunk involvement) would point toward a more extensive plexopathy, which is less common in isolated shoulder pain presentations. 1. Upper trunk (C5-C6) injuries are classically associated with shoulder pain and weakness, as seen in Erb-Duchenne palsy. 2. Despite the mention of forearm weakness, the distribution of deficits usually stems from proximal nerve involvement (upper trunk). 3. A focused neurological exam is critical to delineate the level of brachial plexus involvement. Current clinical guidelines reinforce conservative management with early physical therapy for upper trunk injuries. Recent studies emphasize the importance of early diagnosis and tailored rehabilitation programs to maximize functional recovery, while innovative nerve conduction techniques continue to refine diagnostic accuracy.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "pt with back pain radiating to the left LL, with normal ankle reflex, what muscle involved:",
    "option_a": "superior Gloteus",
    "option_b": "iliopsoas",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "This question examines the localization of radiculopathy based on clinical findings. Patients with back pain radiating to the lower limb typically have nerve root compression. The normal ankle reflex suggests that the S1 nerve root is not involved; therefore, the pathology likely involves a nerve root that supplies muscles other than those mediating the Achilles (S1) reflex. In this context, the involvement of a hip abductor like the gluteus medius (here referred to as 'superior Gloteus') is consistent with an L5 radiculopathy. Lumbar disc herniation or foraminal stenosis can compress nerve roots. The L5 nerve root, for instance, supplies motor fibers to the gluteus medius (innervated via the superior gluteal nerve, predominantly from L4\u2010S1 contributions) and the dorsiflexors. Since the ankle reflex (mediated by S1) is normal, it implies sparing of the S1 component while the L5 segment (impacting the gluteus medius and dorsiflexion) may be compromised. Patients may present with radiating pain and weakness in the distribution of the affected nerve root. With L5 involvement, one might observe gait disturbances \u2013 such as difficulty abducting the hip and foot drop (loss of dorsiflexion) \u2013 even with a normal Achilles reflex. The gluteus medius is critical for pelvic stability during ambulation. Differential diagnoses include disc herniation causing radiculopathy, lumbar spinal stenosis, and even hip pathology. Neurological examination distinguishing reflex integrity (normal ankle reflex here) helps isolate the involved nerve root. Imaging studies like MRI of the lumbar spine confirm the level of compression. Initial management consists of conservative measures: physical therapy, nonsteroidal anti\u2010inflammatory drugs (NSAIDs), and activity modification. If conservative management fails and symptoms persist beyond 6 weeks, further imaging and possibly epidural steroid injections may be considered. In pregnant patients, acetaminophen is preferred for pain and physical therapy is safe; imaging, if indicated, would preferably be done with MRI to avoid ionizing radiation. Option A (superior Gloteus) is taken to represent the gluteus medius \u2013 a muscle innervated by the L5 segment (via the superior gluteal nerve) \u2013 which fits the clinical scenario. Option B (iliopsoas) is innervated by L1\u2013L3 and would not typically be affected in an L5 radiculopathy. The missing options leave no alternative that challenges the rationale for Option A. 1. A normal ankle reflex can help rule out S1 involvement, steering the clinical suspicion towards L5 pathology. 2. Gluteus medius weakness is a key component of L5 radiculopathy leading to an abnormal gait or Trendelenburg sign. Recent guidelines emphasize the importance of correlating clinical findings with imaging when suspecting radiculopathy. Conservative treatment remains the first-line management, with MRI being the preferred imaging modality in persistent cases.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "What is the medication cause neuropathy and myopathy?",
    "option_a": "Dapson",
    "option_b": "Chloroquine",
    "option_c": "Hydralazine",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "This question addresses drug-induced neuromuscular toxicity. Certain medications are known for causing both neuropathy and myopathy as adverse effects, which is important for clinicians to recognize in patients undergoing long-term therapy. Chloroquine accumulates within lysosomes of muscle cells, disrupting autophagic mechanisms and leading to a vacuolar myopathy. Additionally, its toxicity may extend to peripheral nerves causing neuropathic symptoms. This dual pathology is well-documented with chloroquine and its derivative, hydroxychloroquine. Patients on chronic chloroquine therapy, often for autoimmune diseases or malaria prophylaxis, may present with proximal muscle weakness and sensory changes like paresthesia. Recognizing these signs early can prevent irreversible damage. The differential includes steroid myopathy, statin-induced myopathy, and other drug-induced neuromuscular syndromes. A detailed medication history along with muscle enzymes, electromyography (EMG), and muscle biopsy (if needed) can help differentiate these conditions. The primary step is discontinuation or dosage adjustment of the offending agent. Symptomatic treatments include supportive care and rehabilitation. In pregnant or lactating patients, the risk\u2013benefit ratio of continuing chloroquine should be assessed, keeping in mind that prophylactic doses are generally considered safe, but caution is warranted if high doses are used. Option A (Dapson) is more commonly associated with hemolytic anemia and methemoglobinemia, not neuromuscular toxicity. Option B (Chloroquine) is the correct choice as it is known to cause both neuropathy and myopathy. Option C (Hydralazine) is often linked with drug-induced lupus, not neuromuscular toxicity. 1. Always review the patient's medication list when myopathy and neuropathy coexist. 2. Long-term chloroquine use can lead to a reversible myopathy if detected early and managed appropriately. Recent research continues to highlight the neuromuscular adverse effects of chloroquine, underscoring the importance of regular clinical monitoring and early intervention upon noticing muscular or sensory complaints.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Old patient came with sensory motor neuropathy with distal weakness (he has dorsiflexion weakness), weight loss, and malaise; what is the next step:",
    "option_a": "CT chest",
    "option_b": "send for Anti Hu",
    "option_c": "Electrophoresis",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "This case focuses on the evaluation of an older patient with a mixed sensorimotor neuropathy accompanied by systemic symptoms like weight loss and malaise. Such a presentation raises suspicion for a paraneoplastic syndrome, commonly associated with small cell lung cancer. Paraneoplastic neuropathies often result from an immune-mediated process where antibodies (e.g., Anti-Hu) target antigens shared by both tumor cells and neurons. The resultant sensory and motor deficits, particularly distal weakness such as dorsiflexion weakness, reflect neuronal damage due to this autoimmune response. The constellation of neuropathy, weight loss, and systemic malaise in an elderly patient is highly suggestive of an underlying malignancy, especially small cell carcinoma of the lung. Dorsiflexion weakness supports the involvement of peripheral nerves supplying the lower limb. Differential diagnoses include diabetic neuropathy, toxic neuropathies, and paraproteinemic neuropathies (evaluated with electrophoresis). In paraneoplastic syndromes, further evaluation with imaging \u2013 especially a CT scan of the chest \u2013 is prioritized to detect lung tumors. Anti-Hu antibody testing may further support the diagnosis but is not the initial step. The cornerstone of managing paraneoplastic neuropathy is the identification and treatment of the underlying malignancy. A CT scan of the chest is the recommended initial imaging modality to investigate lung cancer. In cases where paraneoplastic antibodies are confirmed, immunotherapy may be considered as adjunctive treatment. In pregnant or lactating patients (though less likely in this typical age group), imaging would need to balance fetal exposure risks, with MRI preferred if necessary. Option A (CT chest) is the correct next step as it directly searches for an underlying lung malignancy. Option B (sending for Anti-Hu) may help confirm paraneoplastic etiology but is usually performed after imaging. Option C (electrophoresis) is more suited for investigating paraproteinemic disorders and does not align with the clinical picture provided. 1. Systemic symptoms such as weight loss and malaise in the context of neuropathy should prompt an evaluation for an underlying malignancy. 2. Paraneoplastic neuropathies often precede the diagnosis of the associated cancer, with small cell lung cancer being a classic example. Current research underscores the importance of early imaging studies in cases of suspected paraneoplastic syndromes. Recent guidelines emphasize a comprehensive work-up that includes both imaging and antibody testing, with CT chest being a critical initial investigation.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "What medication cause sensory ataxia?",
    "option_a": "Pyrodixine",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "This question tests the recognition of drug-induced sensory neuropathies. High-dose pyridoxine (vitamin B6) is a well-known cause of sensory neuropathy, which may manifest clinically as sensory ataxia due to impairment in proprioceptive pathways. Excessive pyridoxine levels lead to toxicity that selectively damages large-diameter sensory nerve fibers. This neurotoxicity disrupts the normal function of the dorsal columns, impairing proprioception and balance, leading to sensory ataxia. Patients with pyridoxine toxicity typically present with symmetrical sensory deficits, paresthesias, and ataxia. Unlike other neuropathies, motor strength is often preserved, and the predominant clinical manifestation is sensory imbalance. The differential includes vitamin B12 deficiency (which also affects the dorsal columns), diabetic neuropathy, and other toxic neuropathies. A detailed history, including medication and supplement use, is key. Laboratory measurements of vitamin B6 levels and exclusion of other causes via B12 levels and glycemic control assessments assist in diagnosis. Management involves promptly discontinuing the excess vitamin B6 and monitoring for gradual improvement in neurological symptoms. Supportive care with physical therapy may be required for gait stabilization. In pregnant or lactating patients, recommended doses of pyridoxine for nausea and vomiting of pregnancy should be strictly adhered to, as excess supplementation can lead to neuropathy. Option A (Pyrodixine, interpreted as pyridoxine) is correct because high doses of vitamin B6 are known to cause sensory ataxia. The absence of other options helps focus on this well-documented association. 1. Even vitamins can be neurotoxic when taken in excess; pyridoxine toxicity is a classic cause of sensory ataxia. 2. A thorough medication and supplement history is essential in patients presenting with neuropathic symptoms. Recent updates confirm that the toxic threshold for vitamin B6 is lower than previously assumed, stressing the need for careful monitoring of dosage in supplement formulations. Clinical guidelines recommend staying within the safe upper intake levels to avoid neurotoxicity.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Young female came with dilated pupils, dysphagia, and descending weakness; what is the Dx?",
    "option_a": "presynaptic NMJ",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Botulism is a neuroparalytic syndrome caused by botulinum toxin that interferes with neuromuscular transmission. It typically presents with a descending flaccid paralysis that starts with cranial nerve involvement, manifesting as dysphagia, dilated or fixed pupils, and progressing to generalized weakness. Botulinum toxin acts at the presynaptic neuromuscular junction by cleaving SNARE proteins that are essential for the release of acetylcholine. This blockade prevents neuromuscular transmission, leading to a characteristic descending paralysis with autonomic dysfunction such as dilated pupils and dry mouth. Evidence supports that early toxin binding and inhibition are key to the development of symptoms. Patients with botulism often present with blurred vision, dilated pupils, dysphagia, and descending weakness. Early involvement of bulbar muscles distinguishes it from disorders that have an ascending pattern. The clinical picture in a young female with these features strongly points to a toxin-mediated presynaptic neuromuscular blockade. The diagnosis is primarily clinical, supported by history (e.g., ingestion of contaminated food) and physical examination findings. Laboratory tests may include detection of botulinum toxin in serum, stool, or food samples. Differential diagnoses include myasthenia gravis (postsynaptic disorder) and Lambert Eaton myasthenic syndrome (a paraneoplastic presynaptic disorder typically seen in older patients), which have differing patterns of weakness and autonomic involvement. Management involves immediate supportive care, including respiratory support if needed, and early administration of botulinum antitoxin to halt progression. Intensive care monitoring is crucial. In pregnancy and lactation, antitoxin therapy is indicated when the clinical benefits outweigh the risks, as untreated botulism can be life-threatening. Adjunctive care with wound management or decontamination (in foodborne cases) is also recommended. Option A ('presynaptic NMJ') is correct because botulism exerts its effect by binding to presynaptic nerve terminals, inhibiting acetylcholine release, and producing the observed symptoms. Other potential options (if provided) such as postsynaptic NMJ dysfunction would be more typical of conditions like myasthenia gravis, which do not present with a descending paralysis pattern. 1. Botulism is characterized by a descending pattern of paralysis and autonomic findings such as dilated pupils. 2. Early recognition and antitoxin administration are critical to prevent respiratory failure. 3. Supportive intensive care management is essential due to the risk of rapid progression. Recent guidelines underscore the importance of early antitoxin administration and respiratory support. Advances in multivalent antitoxin formulations have improved outcomes, and current research focuses on rapid diagnostic methods to expedite therapy.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "scenario of AIDP what is the early findings in NCS:",
    "option_a": "prolonged or absent F wave with absent H Reflex.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "AIDP (Acute Inflammatory Demyelinating Polyradiculoneuropathy) is the most common variant of Guillain\u2013Barr\u00e9 syndrome, an acute immune-mediated disorder affecting peripheral nerves through demyelination. In AIDP, an autoimmune response\u2014often triggered by a preceding infection\u2014attacks the myelin sheaths of peripheral nerves. This demyelination process results in slowed nerve conduction, particularly affecting the proximal nerve segments, which is reflected early on in electrophysiological studies. Clinically, AIDP frequently presents with an ascending pattern of weakness and areflexia. In the early stage, the most sensitive electrophysiologic changes include prolonged or absent F waves and diminished or absent H reflexes, which reflect impaired conduction in proximal nerve segments. Nerve conduction studies (NCS) and electromyography (EMG) are key diagnostic tools. Early findings include prolonged or absent F waves along with absent H reflexes. Differential diagnoses include other causes of acute weakness such as acute myelopathies, metabolic neuropathies, or axonal variants of Guillain\u2013Barr\u00e9 syndrome. The first-line treatments for AIDP include intravenous immunoglobulin (IVIG) and plasmapheresis, both of which have been shown to reduce morbidity. In pregnancy and lactation, IVIG is generally preferred due to its favorable safety profile and extensive use in pregnant patients with autoimmune conditions. Option A is correct because prolonged or absent F waves with absent H reflexes are among the earliest and most consistent electrophysiologic findings in AIDP, highlighting proximal nerve demyelination. 1. Early NCS findings, particularly F wave abnormalities, may be the only initial evidence of AIDP. 2. Prompt initiation of immunotherapy correlates with better clinical outcomes. 3. Close monitoring of respiratory function is essential given the risk of rapid progression. Recent clinical guidelines continue to support the early initiation of IVIG or plasmapheresis in AIDP. Studies have demonstrated that these treatments significantly improve recovery times, with emerging research focusing on biomarker-driven early diagnosis.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Young male patient came with eyelid myotonia increased after eating icecream or exposed to cold; what is the Dx?",
    "option_a": "Paramyotonia congenita",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Paramyotonia congenita is a rare genetic muscle disorder classified among the non-dystrophic myotonias. It is characterized by myotonia (delayed relaxation after contraction) that paradoxically worsens with repeated activity and cold exposure. This condition results from a mutation in the SCN4A gene, which encodes the skeletal muscle sodium channels. The mutation alters channel inactivation, leading to an abnormal, prolonged depolarization of muscle fibers. Cold temperatures exacerbate this dysfunction, intensifying the myotonic response. Patients typically present in childhood or early adulthood with symptoms of muscle stiffness that are noticeably worsened by cold exposure, such as after eating ice cream or exposure to cold weather. Eyelid myotonia\u2014a delay in eyelid relaxation\u2014can be a hallmark finding, helping to distinguish this disorder from other myotonic syndromes. Diagnosis is based on clinical history, family history, and electromyography (EMG) showing characteristic myotonic discharges that intensify with cold testing. Differential diagnoses include myotonic dystrophy (which usually involves multisystem features including cataracts and endocrine abnormalities) and myotonia congenita (Thomsen disease), which often demonstrates a 'warm-up' phenomenon rather than worsening with repeated action. Management primarily involves lifestyle modifications, including avoiding cold exposure and triggers that precipitate episodes. Pharmacologic therapy with sodium channel blockers such as mexiletine is considered first-line for reducing myotonia. In pregnancy and lactation, non-pharmacologic measures (avoiding cold exposure) are preferred, and the use of mexiletine should be evaluated on a case-by-case basis with careful risk\u2013benefit assessment. Option A correctly identifies paramyotonia congenita because the scenario describes eyelid myotonia that worsens with cold exposure\u2014a key feature of this condition. Other options might refer to conditions like myotonic dystrophy (which involves additional systemic findings) or myotonia congenita (which typically exhibits improvement with activity). 1. In paramyotonia congenita, myotonia worsens with repeated muscle activity and cold\u2014a paradoxical response compared to other myotonias. 2. Eyelid myotonia is an important clinical clue to the diagnosis. 3. Avoidance of cold and triggers is central to managing symptoms. Recent studies have validated the efficacy of mexiletine in alleviating myotonia in paramyotonia congenita. Genetic testing for SCN4A mutations has become the gold standard for confirming the diagnosis, and ongoing research is refining both pharmacologic and non-pharmacologic strategies for management.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "scenario of AIDP on day 5 what is the NCS will show?",
    "option_a": "sural sparing with effected median and ulnar",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "In AIDP\u2014a variant of Guillain\u2013Barr\u00e9 syndrome\u2014early nerve conduction study (NCS) findings are critical for diagnosis. A key early feature noted on NCS is the phenomenon of 'sural sparing' where sensory nerve involvement is less pronounced in the sural nerve compared to abnormalities in the motor nerves of the upper limbs. AIDP is characterized by immune-mediated demyelination of peripheral nerves. This demyelination predominantly affects motor nerves (such as the median and ulnar nerves), leading to conduction delays, block, and abnormal F wave responses. The sural nerve, a sensory nerve, is often spared in the early phase because the demyelinating process initially involves proximal nerve segments and motor fibers. Patients with AIDP typically present with ascending weakness and areflexia. By day 5 of the illness, NCS often shows significant abnormalities in the median and ulnar nerves, while the sural nerve remains relatively intact\u2014a pattern that supports the diagnosis of AIDP versus other polyneuropathies. NCS and electromyography (EMG) are essential for diagnosing AIDP. The 'sural sparing' pattern, along with prolonged or absent F waves, guides the clinician towards AIDP over alternative diagnoses such as axonal neuropathies or chronic inflammatory demyelinating polyneuropathy (CIDP). Immediate treatment is necessary to halt disease progression. First-line treatments include IVIG and plasmapheresis, both of which have demonstrated efficacy in AIDP. In pregnant and lactating patients, IVIG is generally considered safe and is preferred due to its well-established safety profile in these populations. Supportive care, particularly respiratory monitoring, is critical. Option A is correct because it describes the electrophysiologic pattern of sural sparing with abnormalities noted in the median and ulnar nerves. This is a recognized early finding in AIDP and helps differentiate it from other neuropathies where the sural nerve is also affected. 1. 'Sural sparing' is an important electrodiagnostic clue in the early phase of AIDP. 2. Early changes on NCS can be subtle, underscoring the importance of serial studies if initial findings are inconclusive. 3. Prompt treatment with IVIG or plasmapheresis can lead to improved outcomes. Contemporary guidelines reaffirm the role of early electrophysiologic testing in diagnosing AIDP. Recent studies continue to support early initiation of immunotherapy (IVIG or plasmapheresis) to improve patient outcomes, with a particular emphasis on recognizing distinctive patterns such as sural sparing in NCS.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Typical case of Hirayama disease right UL weakness with preserved brachioradialis and minimal weakness in the left side UL. what is the associated finding in this patient?",
    "option_a": "focal cervical cord atrophy",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Hirayama disease (monomelic amyotrophy) is a rare, benign motor neuron disorder seen typically in young males. It is characterized by insidious onset of unilateral or asymmetrical atrophy and weakness of the hand and forearm muscles with relative sparing of the brachioradialis muscle (producing the so\u2010called 'oblique amyotrophy'). The underlying mechanism involves abnormal dynamics of the cervical dural sac during neck flexion. This abnormality leads to forward displacement of the posterior dural wall and repeated microtrauma to the lower cervical spinal cord, producing focal chronic ischemia and subsequent atrophy of the anterior horn cells in the lower cervical segments. Patients usually present with slowly progressive weakness and muscle wasting of one upper limb (often the dominant side), with sparing of the brachioradialis muscle. This pattern of involvement correlates with the specific segmental damage in the lower cervical cord seen on imaging. Diagnosis is based on clinical features and confirmed with a flexion MRI of the cervical spine which reveals focal cord atrophy with anteroposterior flattening and forward dural displacement. Differential diagnoses include motor neuron disease (e.g., ALS), multifocal motor neuropathy, and cervical spondylotic myelopathy. Distinguishing features include the age of onset, the pattern of muscle involvement, and radiologic findings unique to Hirayama disease. The mainstay of management is conservative. Patients are advised to avoid prolonged neck flexion; a cervical collar may be used to prevent neck flexion and progression of cord damage. Physical therapy may provide supportive care. In patients who are pregnant or lactating, conservative management remains the first-line approach with non-invasive measures prioritized over surgical interventions. Option A, 'focal cervical cord atrophy', is correct. This is the hallmark radiological finding seen on flexion MRI in Hirayama disease, reflecting the focal damage to the lower cervical cord due to chronic compressive ischemia. \u2022 The classic 'oblique amyotrophy' \u2013 severe atrophy of the hand and forearm muscles with relative sparing of the brachioradialis \u2013 should raise suspicion for Hirayama disease.  \u2022 Flexion MRI of the cervical spine is the key diagnostic test. Recent studies emphasize early diagnosis via dynamic MRI to prevent progression, and there is increasing support for conservative management with a cervical collar to minimize neck flexion. There is ongoing research into the role of surgical intervention for selected severe or progressive cases.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Patient came with channelopathy what is the best work up:",
    "option_a": "long exercise test",
    "option_b": "Short exercise test",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Muscle channelopathies are a group of disorders defined by dysfunction in ion channels of skeletal muscle membranes. These conditions lead to abnormal muscle excitability, manifesting as episodes of myotonia (delayed relaxation) or periodic paralysis. Mutations affecting ion channels (such as sodium, calcium, or potassium channels) alter the electrical properties of muscle fibers. This can result in aberrant firing, prolonged depolarization, or failure to repolarize, all of which contribute to the clinical symptoms seen in channelopathies. Patients with channelopathies typically present with episodic muscle weakness or stiffness. The clinical presentation may vary from myotonia to periodic paralysis. The electrophysiological abnormalities are often demonstrable with specialized tests that provoke the latent channel dysfunction. The long exercise test is a vital electrophysiological study in suspected muscle channelopathies. It involves recording the compound muscle action potential before and after a prolonged period of exercise, and an abnormal decrement is indicative of ion channel dysfunction. Differential diagnoses include myasthenia gravis and metabolic myopathies, but these conditions have distinct clinical and laboratory features. Management is largely symptomatic. Depending on the type of channelopathy, medications such as acetazolamide, dichlorphenamide, or mexiletine may be used. For patients who are pregnant or lactating, treatment decisions must weigh potential fetal/neonatal risks against maternal benefits. In many cases, conservative management and lifestyle modifications (avoiding triggers like strenuous exercise or cold exposure) are recommended. Option A, the long exercise test, is correct. This diagnostic tool is widely used in the evaluation of muscle channelopathies as it helps unmask the abnormal response of muscle fibers after prolonged activity, thereby supporting the diagnosis. \u2022 The long exercise test is particularly useful in identifying decrement in compound muscle action potentials in various channelopathies.  \u2022 Differentiating between the types of channelopathies is crucial, as therapies can be quite specific to the underlying ion channel defect. Recent guidelines underscore the long exercise test as a sensitive instrument in detecting channel dysfunction, and genetic studies continue to refine the classification and management of these conditions.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Scenario typical for paramyotonia congenita; asked about the gene?",
    "option_a": "Na channel",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Paramyotonia congenita is an inherited skeletal muscle disorder characterized by myotonia (delayed muscle relaxation) triggered and worsened by cold and exercise. It belongs to the group of non-dystrophic myotonias. This condition is most commonly caused by mutations in the SCN4A gene, which encodes the alpha\u2010subunit of the voltage\u2010gated sodium channel in skeletal muscles. The mutation leads to impaired channel inactivation, causing a prolonged influx of sodium and sustained muscle fiber depolarization, which manifests clinically as myotonia. Patients typically develop muscle stiffness that worsens with exposure to cold and may exhibit paradoxical worsening with repeated activity (unlike the warm-up phenomenon seen in other myotonic disorders). Symptoms often begin in childhood or adolescence. Diagnosis is based on clinical history, physical examination, and electrophysiological studies (such as EMG, which may reveal myotonic discharges). Cold provocation tests can help elicit symptoms. Genetic testing confirming a mutation in the SCN4A gene clinches the diagnosis. Differential diagnoses include myotonia congenita (linked to CLCN1 gene mutations) and other periodic paralyses. Management focuses on trigger avoidance (especially cold exposure) and symptomatic treatment with sodium channel blockers like mexiletine, which can reduce myotonia. When treating pregnant or lactating women, clinicians must consider that mexiletine is generally classified as a Category C drug; hence, a risk-benefit analysis is essential, and alternative therapies may be explored. Option A, 'Na channel', is correct because paramyotonia congenita results from mutations in the sodium channel gene (SCN4A). This mutation is the definitive molecular abnormality in this condition. \u2022 Cold exposure is a well-known trigger for symptom exacerbation in paramyotonia congenita.  \u2022 Unlike other myotonic disorders, the warm-up phenomenon is absent in paramyotonia congenita. Current research continues to validate the role of SCN4A mutations in the pathogenesis of paramyotonia congenita, and randomized clinical trials support the use of mexiletine for symptomatic relief. Genetic testing is increasingly being used for diagnostic confirmation in ambiguous clinical cases.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "GBS scenario, asking what is the predicting factor for intubation?",
    "option_a": "presence of dysautonomia",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "Guillain-Barr\u00e9 Syndrome (GBS) is an acute, immune-mediated polyradiculoneuropathy that can rapidly progress to involve the respiratory muscles. Early prediction of respiratory failure is critical in managing GBS. GBS involves an autoimmune attack on peripheral nerves leading to demyelination and/or axonal degeneration. When bulbar muscles and the diaphragm are compromised, respiratory failure may ensue. Although dysautonomia is a recognized feature of GBS, it is more relevant to cardiovascular instability rather than a direct predictor of respiratory compromise. Patients with GBS may exhibit rapidly progressive weakness, including bulbar and neck muscles, leading to decreased respiratory effort. A key clinical marker is a reduction in forced vital capacity (FVC) or evidence of bulbar dysfunction, which are directly linked to the risk of needing intubation. Close monitoring of respiratory parameters, including serial measurements of FVC and assessment for bulbar weakness, is essential. Differential diagnoses include conditions like myasthenia gravis and botulism, but the acute ascending weakness pattern and nerve conduction studies help in differentiating GBS. Management of GBS includes close respiratory monitoring and early intervention when signs of respiratory compromise appear. Intubation is typically indicated when FVC falls below 20-30 mL/kg or if bulbar dysfunction is significant. In pregnant or lactating patients, airway management follows the same principles, with additional considerations for fetal monitoring and minimizing drug exposure. While option A (presence of dysautonomia) is an important feature of GBS, it is not the most direct predictor for intubation. The marked answer, option B, likely refers to indicators such as reduced vital capacity or bulbar involvement, which are the best predictors of respiratory failure in GBS. Hence, the marked answer B is correct. \u2022 Bulbar muscle weakness and a rapid decline in forced vital capacity are the most reliable predictors of impending respiratory failure in GBS.  \u2022 Although dysautonomia is common in GBS, it does not directly forecast the need for intubation. Recent guidelines and studies emphasize serial pulmonary function testing and early recognition of bulbar dysfunction as critical in predicting and managing respiratory failure in GBS. Protocols now advocate for objective measurements, such as FVC, to guide timely intubation decisions.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "52 years old female has dyslipidemia on statin, and had pneumonia admitted to the hospital then she started on erythromycine, after few days she developed weakness. Suspected toxic myopathy, what is increased the risk?",
    "option_a": "old age.",
    "option_b": "female",
    "option_c": "recent infection",
    "option_d": "concomitant use of erythromycine",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Neuromuscular",
    "explanation": "Statin-induced myopathy is an adverse drug reaction where muscle toxicity occurs due to elevated statin levels. The risk increases significantly when statins interact with other medications that inhibit their metabolism. Statins are primarily metabolized by the cytochrome P450 system (especially CYP3A4). Drugs like erythromycin are potent CYP3A4 inhibitors. Their concomitant use results in increased plasma concentrations of statins, leading to a dose-dependent risk of muscle injury and toxic myopathy. Patients on statin therapy may experience muscle pain, weakness, and elevated creatine kinase levels. In this scenario, the patient developed weakness after starting erythromycin for pneumonia, pointing to a drug interaction precipitating myopathy. Evaluation involves a detailed medication history, measurement of serum creatine kinase levels, and electromyography if needed. Differential diagnoses include inflammatory myopathies, hypothyroid myopathy, and other drug-induced myopathies. First-line management is discontinuation or adjustment of the offending agents. Alternative antibiotics that do not inhibit CYP3A4 may be considered. Supportive care and monitoring of CK levels are important. In patients of childbearing potential (pregnancy or lactation), it is crucial to note that statins are contraindicated, and alternative lipid-lowering strategies should be used. Option D (concomitant use of erythromycin) is correct because erythromycin inhibits CYP3A4 leading to increased statin levels. Although advanced age, female gender, and recent infection can be risk factors, the drug interaction is the most critical precipitant in this setting. 1) Always assess for potential drug interactions when initiating new therapies in patients on statins. 2) Erythromycin and other macrolide antibiotics are potent CYP3A4 inhibitors and require caution. 3) Monitor for signs of myopathy, especially in high-risk populations. Recent guidelines and pharmacovigilance studies emphasize the importance of avoiding CYP3A4 inhibitors in patients on statins. Updated clinical reviews recommend reviewing all medication lists to minimize the risk of adverse drug interactions leading to myopathy.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "15 years old male has myotonia and weakness improved after excercise, his father has the same, what is the Dx?",
    "option_a": "Thomson",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Congenital myotonia is a muscle channelopathy characterized by delayed relaxation of muscles after contraction. It is often classified into autosomal dominant and autosomal recessive forms. Mutations in the CLCN1 gene, encoding the skeletal muscle chloride channel, lead to hyperexcitability of the muscle cell membrane. In the autosomal dominant (Thomsen disease) type, a single mutant allele is sufficient to cause symptoms. A hallmark of the condition is the 'warm\u2010up phenomenon,' where myotonia improves with repeated exercise. A family history, such as an affected father, supports an autosomal dominant inheritance pattern as seen in Thomsen disease. Diagnosis is based on clinical evaluation, electromyography (EMG) showing myotonic discharges, and genetic testing to confirm CLCN1 mutations. Differential diagnoses include other myotonic disorders such as myotonic dystrophy. First-line management includes symptomatic treatment with sodium channel blockers such as mexiletine. Physical therapy can help improve muscle function. In pregnancy and lactation, mexiletine should be used with caution, and risk-benefit analysis is required because these patients require management of symptoms while minimizing fetal exposure. Option A (Thomsen) is correct as it refers to Thomsen disease, the autosomal dominant form of myotonia congenita. The presence of a similarly affected father reinforces the dominant pattern. 1) The 'warm-up phenomenon' (improvement of myotonia with exercise) is a key diagnostic clue. 2) A positive family history suggests autosomal dominant transmission. 3) Electromyography often reveals characteristic myotonic discharges. Recent studies emphasize that genetic confirmation via CLCN1 mutation analysis is the gold standard for diagnosis. Updated reviews confirm mexiletine as an effective agent in managing symptoms in congenital myotonia.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Young patient came with weakness and he can't extend his elbow and had toe walking; ECG showed RBBB; what is the Dx?",
    "option_a": "Emery Drafus.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Emery-Dreifuss Muscular Dystrophy (EDMD) is a form of muscular dystrophy characterized by early contractures, muscle weakness, and cardiac abnormalities. EDMD is caused by mutations in genes such as EMD (encoding emerin) or LMNA (encoding lamin A/C). These mutations lead to defects in the nuclear envelope, resulting in progressive muscle wasting, early joint contractures (particularly at the elbows and Achilles tendons), and conduction system abnormalities in the heart. The clinical features include difficulty with joint extension (particularly at the elbows), toe walking due to contractures of the Achilles tendon, and cardiac conduction defects such as right bundle branch block (RBBB). The combination of musculoskeletal and cardiac involvement is suggestive of EDMD. Diagnosis is based on clinical evaluation, family history, ECG findings (e.g., RBBB or other conduction abnormalities), and confirmatory genetic testing. Differential diagnoses include other muscular dystrophies like Duchenne or Becker, though these tend to show different patterns of muscle involvement and contractures. Management includes regular cardiac monitoring with ECGs and echocardiograms. When conduction abnormalities become significant, pacemaker or defibrillator implantation may be necessary. Orthopedic interventions and physical therapy can help manage contractures. In the context of pregnancy and lactation, multidisciplinary management is vital to monitor both maternal cardiac status and musculoskeletal function while minimizing fetal risks. Option A (Emery-Dreifuss Muscular Dystrophy) is correct because the combination of elbow contractures, toe walking, and ECG abnormalities (RBBB) fits the classic description of EDMD. Other muscular dystrophies do not typically present with this specific triad of features. 1) Early elbow contractures in a young patient should raise suspicion for EDMD. 2) Cardiac conduction defects in muscular dystrophy warrant prompt cardiology evaluation. 3) Family history and genetic testing are crucial in differentiating EDMD from other muscular dystrophies. Recent guidelines stress the importance of early detection of cardiac involvement in EDMD to reduce the risk of sudden cardiac death. Advances in genetic testing have improved diagnostic accuracy and allowed for better family counseling.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "scenario with Amyloidosis what to do next:",
    "option_a": "Fat aspiration",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Amyloidosis is a disorder characterized by the extracellular deposition of amyloid proteins in various tissues, leading to organ dysfunction. Early and accurate diagnosis is critical. Amyloid deposits result from the misfolding of normal proteins (commonly immunoglobulin light chains in AL amyloidosis) that aggregate into fibrils. These deposits interfere with normal organ architecture and function. Patients with systemic amyloidosis may present with a range of symptoms from restrictive cardiomyopathy to nephrotic syndrome. A fat pad aspiration is a minimally invasive diagnostic tool that can confirm the presence of amyloid deposits in patients with suspected systemic amyloidosis. The diagnostic workup involves tissue biopsy examined with Congo red staining, which demonstrates apple-green birefringence under polarized light. Differential diagnoses include localized amyloidosis and other protein deposition disorders; however, fat pad aspiration is widely used because it is less invasive than organ biopsies. The management strategy depends on the amyloid subtype. For AL amyloidosis, first-line treatment involves chemotherapy regimens (e.g., bortezomib-based) to reduce the light-chain production. For transthyretin amyloidosis, novel therapies like tafamidis are used. In the setting of pregnancy and lactation, treatment requires careful consideration, balancing maternal benefits with fetal safety; many chemotherapy agents are contraindicated, necessitating specialized care. Option A (Fat aspiration) is correct because abdominal fat pad aspiration is often the first diagnostic test performed due to its safety, simplicity, and reasonable sensitivity for detecting systemic amyloidosis. 1) When amyloidosis is suspected, a fat pad aspiration offers a quick and minimally invasive diagnostic method. 2) Congo red staining with apple-green birefringence is the diagnostic hallmark of amyloid deposition. 3) Early diagnosis can significantly alter management and improve outcomes. Recent research supports the use of fat aspirate biopsies in suspected amyloidosis with improved sensitivity and specificity. Updated consensus guidelines emphasize early intervention based on amyloid typing, with emerging therapies showing promise in altering disease progression.",
    "exam_year": "2021",
    "exam_type": "Part II"
  }
]